1. Home
  2. NTR vs ONC Comparison

NTR vs ONC Comparison

Compare NTR & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutrien Ltd.

NTR

Nutrien Ltd.

N/A

Current Price

$67.18

Market Cap

34.2B

Sector

Industrials

ML Signal

N/A

Logo BeiGene Ltd. American Depositary Shares

ONC

BeiGene Ltd. American Depositary Shares

N/A

Current Price

$359.05

Market Cap

40.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NTR
ONC
Founded
2017
2010
Country
Canada
Switzerland
Employees
N/A
12000
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.2B
40.6B
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
NTR
ONC
Price
$67.18
$359.05
Analyst Decision
Buy
Strong Buy
Analyst Count
22
10
Target Price
$75.45
$385.10
AVG Volume (30 Days)
2.3M
413.2K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
2.95%
N/A
EPS Growth
N/A
140.43
EPS
N/A
0.31
Revenue
N/A
$238,387,000.00
Revenue This Year
$4.03
$723.76
Revenue Next Year
N/A
$15.04
P/E Ratio
$18.99
$1,158.94
Revenue Growth
N/A
22179.16
52 Week Low
$53.03
$253.95
52 Week High
$85.36
$385.22

Technical Indicators

Market Signals
Indicator
NTR
ONC
Relative Strength Index (RSI) 48.88 75.74
Support Level $58.83 $305.66
Resistance Level $70.10 $371.94
Average True Range (ATR) 1.85 7.63
MACD -0.25 3.03
Stochastic Oscillator 40.44 84.69

Price Performance

Historical Comparison
NTR
ONC

About NTR Nutrien Ltd.

Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients—nitrogen, potash, and phosphate—although its main focus is potash, where it is the global leader in installed capacity with a roughly 20% market share. The company is also the largest agricultural retailer in North America and Australia, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.

About ONC BeiGene Ltd. American Depositary Shares

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

Share on Social Networks: